bioaffinitytech.com (BIAF) - Koefisien rega marang bathi

bioAffinity Technologies (BIAF) relies on partnerships with clinics for biomaterial collection, conducting analyses using its own proprietary software solutions. The company is implementing the non-invasive CyPath Lung method, which enables early-stage lung cancer detection via sputum cytometry. This price chart reflects a market trend for the asset with a P/E ratio of -0.20, correlating with rising demand for rapid diagnostics among American pulmonologists.

The efficiency of bioAffinity Technologies (BIAF) oncology diagnostic software depends on the stability of partner networks for biomaterial collection. By analyzing the company's relative P/E ratio, an investor can observe the business value dynamics relative to its net income. This metric measures the investment payback period by comparing market capitalization with actual cash flow. The extremes of this curve signal whether the asset is overvalued or undervalued. This confirms the resilience of the financial model despite moderate operational dependency.